GlassScriptPhysician profile
Angela M Bretton
NPI 1750827895
$7,150.43
in general payments reported to CMS, 2019-2025
23 companies · $2,636 in 2025
The $2,636 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $1,252 · 2023: $1,436 · 2024: $1,242 · 2025: $2,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,972 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,281 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,281.00 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,394.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $842.16 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $565.14 | 2021-2025 | Hizentra, Andembry |
| Astrazeneca Pharmaceuticals LP | $510.38 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $471.33 | 2021-2025 | |
| Grifols USA, LLC | $462.70 | 2022-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $413.79 | 2021-2025 | Glassia, Cuvitru, Takhzyro |
| Amgen INC. | $397.47 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $347.10 | 2021-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $125.00 | 2022 | |
| Leo Pharma INC. | $98.10 | 2022-2024 | Adbry |
| Optinose US, INC. | $94.40 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.65 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Pfizer INC. | $60.34 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.73 | 2022 | |
| Seqirus USA INC | $36.95 | 2023-2024 | Flucelvax Quadrivalent, Flucelvax |
| Biocryst US Sales Co., LLC | $34.74 | 2025 | Orladeyo |
| Hospira, INC. | $30.99 | 2022 | |
| Octapharma USA, INC. | $22.45 | 2024 | Cutaquig |
| Bio Products Laboratory USA, INC. | $22.41 | 2023 | Coagadex, Gammaplex |
| Kaleo, INC. | $16.05 | 2023 | Auvi-Q |
| Grifols Shared Services North America, INC. | $14.38 | 2025 | Xembify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Bretton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.